78 results
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
5 Mar 24
Regulation FD Disclosure
11:00am
pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
13 Feb 24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
4:57pm
rights; and the impact of the ongoing COVID-19 pandemic on MyMD’s results of operations, business plan and the global economy. A discussion
8-K
EX-99.1
MYMD
MyMD Pharmaceuticals Inc
6 Dec 23
Regulation FD Disclosure
9:15am
pandemic on MyMD’s results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth
8-K
EX-99.1
dhmdwm3 at
19 Oct 23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
9:00am
8-K
EX-99.1
83tdw7 q5
4 Oct 23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4:30pm
8-K
EX-99.1
tlxmjh0
14 Aug 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
boc423l3h2ph3baey
31 Jul 23
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline
9:00am
8-K
EX-99.1
08o0k 1t1jyjgha
12 Apr 23
Regulation FD Disclosure
8:45am
8-K
EX-99.1
33p w1zj5
8 Dec 22
MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
4:15pm
8-K
EX-99.1
99d1h16xfo
18 Nov 22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
4:30pm
8-K
EX-99.1
inp0zn95a6e ig6fyn
14 Nov 22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
8:32am
8-K
EX-99.1
7u7q5 zm26ljq2tiq
20 Sep 22
Efficacy data anticipated in Q4 of 2022
8:00am
8-K
EX-99.1
tenuouk ucx
31 Aug 22
Mymd Pharmaceuticals Receives Grant from European
8:00am
424B5
8s6n scac1nthk0walqe
17 Aug 22
Prospectus supplement for primary offering
3:00pm